Comprehensive, up-to-date information on HIV/AIDS treatment, prevention, and policy from the University of California San Francisco

CME Credit Available: 1 AMA PRA Category 1 Credit ($25 fee)
Course Number: MED1409R
Presentation Date: June 1, 2011
CME Release Date: March 1, 2011
CME Expiration Date: March 1, 2014

Anyone can browse or listen to this resource free of charge. Users who are requesting CME credit are required to complete an evaluation and a CME application, and to pay a $25 processing fee to the UCSF Office of Continuing Medical Education.

Dr. Volberding discusses the recent shifts in U.S. HIV treatment guidelines, especially regarding early initiation of ART, and reviews data on efficacy of ARVs in preventing sexual transmission of HIV. He discusses both ART for HIV-infected persons and preexposure prophylaxis for uninfected persons.

Presenter: Paul A. Volberding, MD,

Dr. Volberding is a professor and vice chair of the Department of Medicine and director of the Center for AIDS Research at the University of California, San Francisco (UCSF), and Chief of Medical Services at the San Francisco Veterans Affairs Medical Center. Dr. Volberding?s professional activities centered for more than 20 years at SFGH, where he established a model program of AIDS patient care, research, and professional education. His research career began with investigations of HIV-related malignancies, especially Kaposi's sarcoma. His primary research focus, however, shifted to clinical trials of antiretroviral drugs. He has been instrumental in testing many compounds, but is best known for groundbreaking trials establishing standards of care for the use of zidovudine in asymptomatic HIV infection and for continuous service on the two major guidelines panels for antiretroviral therapy.

Medical Editor: Susa Coffey, MD

Dr. Coffey is Associate Professor of Medicine and attending physician at the UCSF Positive Health Program (PHP) at San Francisco General Hospital, and Medical Editor at HIV InSite. Dr. Coffey is in practice at the two UCSF-affiliated HIV/AIDS clinics at San Francisco General Hospital and on the UCSF Parnassus campus.

Dr. Coffey and Dr. Volberding have no financial disclosures. This educational activity was supported with a gift from Roche Molecular Diagnostics.

HIV InSite offers this activity in conjunction with the University of California San Francisco (UCSF) Office of Continuing Medical Education. The UCSF Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The UCSF Office of Continuing Medical Education designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This CME activity is offered from March 1, 2011, to March 1, 2014. Participants who successfully complete the activity posttest and submit the evaluation and registration forms are eligible to receive CME credit. Physicians (MDs, DOs, and international equivalents) may receive CME credit for completing this activity.

This Center for AIDS Prevention Studies (CAPS) CME activity was made possible through grants from Roche Molecular Diagnostics, and a the NIAID-funded UCSF-GIVI Center for AIDS Research. For those who want CME credit, there is a $25 processing fee, which goes to the UCSF Office of Continuing Medical Education.

If you have any questions about this CAPS CME activity, please contact the UCSF Office of Continuing Medical Education:

UCSF Office of Continuing Medical Education
3333 California Street, Room 450
San Francisco, CA 94118
Phone: 415-476-4251
Fax: 415-476-0318
Registration: 415-476-5808
Registration Fax: 415-502-1795
email: info@ocme.ucsf.edu